Moneycontrol PRO
you are here: HomeNewsGeneric drugs
generic drugs
Jump to
39 Results Found
  • India woos ASEAN with generics production, vaccines; wants support in IPR waiver Sep 17, 2021 01:27 PM IST

    India woos ASEAN with generics production, vaccines; wants support in IPR waiver

    Apart from securing the support of ASEAN nations for the global intellectual property waiver for COVID vaccines, the move is also aimed at pulling closer the traditional partners in the bloc, who have become close to China, sources say

  • Veterans Unpacked | D.S. Brar: "Your network is your net worth, and your credibility is your currency" Jul 31, 2021 01:27 PM IST

    Veterans Unpacked | D.S. Brar: "Your network is your net worth, and your credibility is your currency"

    His advice to young leaders: "Focus on relationships and building trust with your customers, your partners and your employees."

  • Reporter's Take | How safe are generic drugs? Jan 03, 2020 07:33 PM IST

    Reporter's Take | How safe are generic drugs?

    Moneycontrol’s Shraddha Sharma talks to Viswanath Pilla to know more about the debate and if there are solutions to it.

  • Lupin denies price manipulation allegations, says will defend antitrust lawsuit in US May 15, 2019 09:45 PM IST

    Lupin denies price manipulation allegations, says will defend antitrust lawsuit in US

    Lupin was named as a defendant with respect to 11 generic drugs for alleged price manipulation.

  • Comment | Cipla takes a calculated risk with generic Sensipar launch Mar 08, 2019 08:10 AM IST

    Comment | Cipla takes a calculated risk with generic Sensipar launch

    Cipla’s launch of a blockbuster drug made by Amgen even while litigation is ongoing is a risky affair. Here’s why Cipla may have taken a calculated risk

  • Comment | US FDA to get a new chief, watch for side effects on pharma shares Mar 07, 2019 08:07 AM IST

    Comment | US FDA to get a new chief, watch for side effects on pharma shares

    The US FDA has been driving generic drug approvals under its current commissioner. His resignation raises a question mark on whether life could change for Indian pharmaceutical companies

  • Modi’s proposed law on docs using generic name in prescriptions gets MSF vote Apr 24, 2017 06:08 PM IST

    Modi’s proposed law on docs using generic name in prescriptions gets MSF vote

    MSF said the unhealthy nexus between doctors and pharma companies encourages over prescription of expensive medicines.

  • Govt to make generic drugs mandatory Apr 18, 2017 09:59 PM IST

    Govt to make generic drugs mandatory

  • Torrent Pharma to acquire clutch of generic brands from Novartis Apr 10, 2017 04:28 PM IST

    Torrent Pharma to acquire clutch of generic brands from Novartis

    As global drug makers are exiting low priority brands, their Indian counterparts are lapping up the opportunity buying established products at perhaps low valuations.

  • Despite regulatory issues, pharma regulators positive on outlook Feb 23, 2017 10:00 PM IST

    Despite regulatory issues, pharma regulators positive on outlook

    There's no end in sight for the Indian pharmaceutical industry's struggles with domestic and foreign drug regulators. It's true that quite a few companies have received clean chits from regulators in the US, UK and Europe. However, at the same time, new issues have also been cropping up with disturbing frequency.

  • Q3 results: Five trends to watch out from Indian drugmakers Jan 14, 2017 02:00 PM IST

    Q3 results: Five trends to watch out from Indian drugmakers

    Analysts predict Q3 to be a tough quarter with revenue growth moderating to 11.7 percent in October-December period compared to 18.4 percent compounded annual growth rate (CAGR) over last 10 years

  • Serial testers, hasty checks: India's flawed generic drug trials Dec 28, 2016 11:04 AM IST

    Serial testers, hasty checks: India's flawed generic drug trials

    HYDERABAD (Reuters) - Vasudeva Prakash left his job as a mechanic in Hyderabad three years ago for what he calls a more lucrative career: taking part in clinical trials on generic drugs.

  • Pharma industry eyes generic drug exports to Japanese market Nov 21, 2016 09:42 PM IST

    Pharma industry eyes generic drug exports to Japanese market

    Appaji said the country exports its one-third pharma products to US alone. "But we are looking at more opportunities in Japan and Latin American markets," he said.

  • Hillary win may pose pricing challenges for pharma cos: Report Nov 07, 2016 07:58 PM IST

    Hillary win may pose pricing challenges for pharma cos: Report

    A Democrat sweep in US polls may pose even greater pricing challenges for the pharma industry and pave the way for tighter pricing regulations for both brand name and generic drugs, according to a report.

  • Time to do more to retain ownership of US market: Dilip Shanghvi Jun 08, 2016 10:09 PM IST

    Time to do more to retain ownership of US market: Dilip Shanghvi

    Over the last year, regulatory hassles have made US market tougher to navigate for Indian companies. Sun Pharmaceutical MD Dilip Shanghvi, however, says this is the time to dig in, and do more to maintain ownership of that market.

  • Indian cos get USFDA nod for 14 first-time generic drugs in 2015 Apr 15, 2016 06:50 PM IST

    Indian cos get USFDA nod for 14 first-time generic drugs in 2015

    Major domestic firms such as Sun Pharma, Lupin, Glenmark, Aurobindo, Alembic and Hetero Labs figure in the list of first-time generic drug approvals released by the FDA's Office of Generic Drugs.

  • EU ban on GVK-tested drugs a 'great concern': Sitharaman Aug 20, 2015 08:19 AM IST

    EU ban on GVK-tested drugs a 'great concern': Sitharaman

    India, on Wednesday, expressed concern over EU's ban on medicines clinically tested by GVK Biosciences, saying it could lead to 'adverse campaign' about clinical trials done in the country.

  • Strides Arcolab to buy Aspen's generic biz in Australia May 21, 2015 01:02 PM IST

    Strides Arcolab to buy Aspen's generic biz in Australia

    The new business will operate under Arrow Pharma and sell 140 generic drugs. The transaction will be financed by internal accruals and debt financing. The acquisition will be EPS accretive immediately.

  • Indian drugmakers see US sales hit by delay in new nods Nov 12, 2014 08:34 AM IST

    Indian drugmakers see US sales hit by delay in new nods

    India's USD 15 billion pharmaceutical industry, which has been hit by a spate of regulatory sanctions in the past year due to concerns about production processes, supplies about 40 percent of generic and over-the-counter drugs to the United States.

  • Cipla targets $5-billion revenue by 2020 Aug 22, 2013 10:28 PM IST

    Cipla targets $5-billion revenue by 2020

    Leading pharma player Cipla said it has targeted a revenue of USD 5 billion by 2020, of which USD 1 billion will come from the US market.

  • Dr Reddy's recalls 3 lots of Ranitidine tablets in the US Aug 22, 2013 02:14 PM IST

    Dr Reddy's recalls 3 lots of Ranitidine tablets in the US

    According to the US FDA, Dr Reddy's initiated recall of the antacid in 150mg strength voluntarily.

  • Analysts raise Sun Pharma FY14 estimates post Q1 results Aug 12, 2013 11:26 AM IST

    Analysts raise Sun Pharma FY14 estimates post Q1 results

    Sun Pharma wrote-off Rs 2,517 crore to settle a patent litigation with Pfizer, which resulted in a consolidated Q1 net loss of Rs 1,276 crore. However, adjusted profit jumped 56 percent and revenue was up 32 percent, sending the stock up over 8 percent.

  • Sun Pharma Q1 net profit seen up 30% to Rs 1,035cr Aug 08, 2013 06:24 PM IST

    Sun Pharma Q1 net profit seen up 30% to Rs 1,035cr

    Sun Pharma's revenue is expected to rise 23 percent year-on-year to Rs 3,287 crore, driven by over 20 percent growth in US sales. Domestic formulations sales are, however, likely to be lower due to the impact of the new drug pricing policy.

  • Dr Reddy's Q1 net up lower-than-expected 7% to Rs 361cr Jul 30, 2013 03:36 PM IST

    Dr Reddy's Q1 net up lower-than-expected 7% to Rs 361cr

    The generic drugs maker's revenue in April-June also missed analysts expectations, growing 12 percent to Rs 2,845 crore. Growth was particularly hurt by a decline in generic drugs sales in Europe and slow growth in Russia. India generics business growth was also flat.

  • Dr Reddy's Q1 net profit seen up 25% YoY to Rs 421 cr Jul 29, 2013 06:17 PM IST

    Dr Reddy's Q1 net profit seen up 25% YoY to Rs 421 cr

    The generic drugs maker's earnings will be boosted by strong growth in the US and Russian generics drugs market and better currency realisations.

Sections
ISO 27001 - BSI Assurance Mark